Back to News
Market Impact: 0.7

Why Jim Cramer backs Meta's AI spending — and the latest on Apple and Amazon ahead of earnings

SPYQQQBMYMSFTMETAAAPLAMZNHOODFEBAYARMCVS
Corporate EarningsTechnology & InnovationArtificial IntelligenceCompany FundamentalsTrade Policy & Supply ChainTax & TariffsHealthcare & BiotechMarket Technicals & Flows
Why Jim Cramer backs Meta's AI spending — and the latest on Apple and Amazon ahead of earnings

U.S. stocks, with the S&P 500 and Nasdaq hitting fresh all-time highs, were propelled by strong earnings from tech giants Microsoft and Meta Platforms. Microsoft's robust Azure cloud growth pushed its market capitalization above $4 trillion, while Meta's AI-driven momentum led to a significant 12% stock surge, fueling broader AI sector optimism. Concurrently, Bristol Myers Squibb shares declined over 4% despite a beat-and-raise quarter, as investor attention shifted to an impending drug trial outcome. Market sentiment was further supported by optimism from U.S. Treasury Secretary Scott Bessent regarding a potential trade deal with China, alongside a new 15% tariff agreement with South Korea. Investors now anticipate earnings from Apple and Amazon, with e-commerce sales being a key determinant for Amazon's performance.

Analysis

The market is experiencing a rally concentrated in mega-cap technology, with the S&P 500 and Nasdaq reaching new all-time highs fueled by strong earnings from Microsoft and Meta Platforms. Microsoft's shares rose over 4% on robust Azure cloud growth, pushing its market capitalization above $4 trillion, while Meta surged approximately 12% due to powerful AI-driven momentum in engagement and advertising. Both firms' commitment to billions in further AI investment reinforces the durability of this secular theme. In contrast, the healthcare sector shows a dislocation, with Bristol Myers Squibb declining more than 4% despite a beat-and-raise quarter. This negative reaction indicates that investors are discounting current financial performance and are instead focused on the binary outcome of the upcoming trial for its drug Cobenfy. The broader market sentiment is also supported by positive macro developments, including a potential U.S.-China trade deal and a new 15% tariff agreement with South Korea. Investor attention now shifts to upcoming earnings from Apple, where concerns about tariff exposure and moderating services growth are present, and Amazon, where strong cloud and advertising performance is anticipated but e-commerce results remain the primary swing factor.